Arsenic trioxide in multiple myeloma: Rationale and future directions

Cancer Journal

Volumn 8, Issue 1, 2002, Pages 12-25

  Anderson, Kenneth C ^a,e   Boise, Lawrence H ^b   Louie, Robert ^c   Waxman, Samuel ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Cell Therapeutics Inc   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Cellular redox; Clinical trials; Multiple myeloma; Trisenox

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ARSENIC TRIOXIDE; ARSENOUS ACID DERIVATIVE; ASCORBIC ACID; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; LOMUSTINE; MELPHALAN; NITROSOUREA; POTASSIUM ARSENITE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOCYTE DISORDER; MORPHOLOGY; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; OXIDATION REDUCTION REACTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SKIN DISEASE; SURVIVAL TIME; SYPHILIS; TOOTH DISEASE; TUMOR GROWTH; DRUG EFFECT; PATHOLOGY; PROGNOSIS; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CLINICAL TRIALS; HUMANS; MULTIPLE MYELOMA; OXIDATION-REDUCTION; OXIDES; PROGNOSIS; TIME FACTORS;

EID: 0036358635     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200201000-00003     Document Type: Review

References (92)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
2. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-3324.
3. Soignet SL, Maslak P, Wang Z-G et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
4. Zhang W, Ohnishi K, Shigeno K et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-1391.
5. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931;97:3-5.
6. Kandel EV, LeRoy GV. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia. Arch Intern Med 1937;60:846-866.
7. Novick SC, Warrell RP Jr. Arsenicals in hematologic cancers. Semin Oncol 2000;27:495-501.
8. Munshi N. Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist 2001;6[suppl 2]:17-21.
9. 3) in high risk refractory multiple myeloma [abstract 541]. Blood 1999;94[10 suppl pt 2]:123a.
10. Munshi NC, Barlogie B, Desikan KR et al. Novel approaches in myeloma therapy. Semin Oncol 1999;26:28-34.
11. Konkola K. More than a coincidence? The arrival of arsenic and the disappearance of plague in early modern Europe. J Hist Med Allied Sci 1992;47:186-209.
12. Aronson SM. Arsenic and old myths. R I Med 1994;77:233-234.
13. 3) in the treatment of APL: II. Remission induction in relapsed patients and pharmacokinetics [abstract 1158]. Blood 1996;88[suppl 1]:292a.
14. Knock FE, Galt RM, Oester YT et al. The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer. Surg Gynecol Obstet 1971;133:458-466.
15. Snow ET. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 1992;53:31-65.
16. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998;55:1747-1758.
17. Jing Y, Dai J, Chalmers-Redman RM et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-2111.
18. 3) + ascorbic acid for the treatment of refractory/relapsed multiple myeloma [abstract]. Presented at the VIIIth International Myeloma Workshop of the Multiple Myeloma Research Foundation; May 4-8, 2001; Banff, Alberta, Canada.
19. Tarnowski GS, Schmid FA, Cappuccino JG et al. Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals. Cancer Res 1966;26[3 pt 2]:181-206.
20. Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996:1649-1672.
21. Sun HD, Ma L, Hu X-C et al. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992; 12:170-172.
22. Sun H-D, Ma L, Hu C-X et al. Thirty-two cases of treating acute promyelocytic leukemia by Ailing-1 (cancer-cure-1) therapy combined with syndrome differentiation treatment of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992;12:170-171.
23. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
24. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-62.
25. Prescribing information: Trisenox™ (arsenic trioxide) injection. 2000. Seattle, WA: Cell Therapeutics, Inc. http://www.cticseattle .com/pdf/TRISENOX_pi.pdf Accessed July 24, 2001.
26. Soignet S, Frankel S, Tallman M et al. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL) [abstract 3084]. Blood 1999;94[suppl 1, pt 1 of 2]:698a.
27. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 2001;6[suppl 2]:11-16.
28. Drach J, Kaufmann H, Urbauer E et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000;126:441-447.
29. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995;85:3365]. Blood 1995; 85:436-447.
30. American Cancer Society. Multiple Myeloma Cancer Resource Center, 1999. http://www.cancer.org/downloads/CRI/CRC_-_ MULTIPLE_MYELOMA.pdf. Accessed October 17, 2001.
31. Kyle RA. Multiple myeloma, macroglobulinemia, and the monoclonal gammopathies. Curr Pract Med 1999;2:1131-1137.
32. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999;36[1 suppl 3]:14-20.
33. Dally A. Thalidomide: was the tragedy preventable? [see comments]. Lancet 1998;351:1197-1199.
34. Sklar C, Whitton J, Mertens A et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227-3232.
35. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
36. Witzig TE. The role of adhesion receptors in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1127-1143.
37. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999;13:1295-1314, xi.
38. Urashima M, Chauhan D, Uchiyama H et al. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995;85:1903-1912.
39. Urashima M, Ogata A, Chauhan D et al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood 1996;87:1928-1938.
40. Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-1112.
41. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248-250.
42. Arron JR, Vologodskaia M, Wong BR et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (TRANCE) and CD40L-mediated Akt activation. J Biol Chem 2001;276:30011-30017.
43. Kapahi P, Takahashi T, Natoli G et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 2000;275:36062-36066.
44. Baldwin AS, Jr. Series introduction: The transcription factor NF-κB and human disease. J Clin Invest 2001;107:3-6.
45. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
46. Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073.
47. Munshi N, Wilson CS, Penn J et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvesel density (MVD) in bone marrow biopsies [abstract 400]. Blood 1998;92:98a.
48. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
49. Lacey DL, Timms E, Tan H-L et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
50. Shipman CM, Rogers MJ, Apperley JF et al. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma 1998;32:129-138.
51. L are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999;107:392-395.
52. Harousseau JL. Intensive therapy in multiple myeloma. Pathol Biol (Paris) 1999;47:203-209.
53. Harousseau J-L, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997;34[1 suppl 1]:61-66.
54. Tricot G, Sawyer JR, Jagannath S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997;15:2659-2666.
55. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-4010.
56. Nishida K, Tamura A, Nakazawa N et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myelomaand plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-534.
57. Attal M, Harousseau J-L. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997;11:133-146.
58. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 5th vol, 2nd ed. Philadelphia: Lippincott-Raven, 1997: 2344-2387.
59. Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998;21:1101-1107.
60. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6[suppl 2]:3-10.
61. Zhu J, Koken MH, Quignon F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:3978-3983.
62. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052-1061.
63. Zhu X-H, Shen Y-L, Jing Y-K et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
64. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326[pt 1]:1-16.
65. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
66. Huang X-J, Wiernik PH, Klein RS et al. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999;16:58-64.
67. Kroemer G, de Thé H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-745.
68. 3) in the treatment of chronic myelogenous leukemia: in vitro and in vivo studies [abstract 4457]. Blood 1999;94[10 suppl 1, pt 2]:278b.
69. Dai J, Weinberg RS, Waxman S et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
70. Boise LH, Lee KP, Reis I, et al. Role of glutathione depletion in arsenic-based treatment [abstract]. Presented at the VIIIth International Myeloma Workshop of the Multiple Myeloma Research Foundation; May 4-8, 2001; Banff, Alberta, Canada.
71. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:776-780.
72. 2 family members [abstract 2631]. Blood 1998;92[10 suppl 1, pt 1]:638a.
73. Park WH, Seol JG, Kim ES et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065-3071.
74. 1 phase accumulation by arsenic trioxide in an adult T-cell leukemia cell line, MT-1 [abstract 4385]. Blood 1999;94[suppl 1]:263b.
75. Chen G-Q, Zhu XH, Shen Y-L et al. Pharmacologic concentrations of arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytes and multiple myeloma cells [abstract 2632]. Blood 1998;92[10 suppl 1 pt 1]:638a.
76. Roboz GJ, Dias S, Lam G et al. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525-1530.
77. Lew YS, Brown SL, Griffin RJ et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-6037.
78. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma [published erratum appears in N Engl J Med 2000;342:364]. N Engl J Med 1999;341:1565-1571.
79. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
80. Roussel RR, Barchowsky A. Arsenic inhibits NF-κB-mediated gene transcription by blocking IκB kinase activity and IκBα phosphorylation and degradation. Arch Biochem Biophys 2000;377:204-212.
81. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
82. Chauhan D, Hideshima T, Rosen S et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-24456.
83. Hideshima T, Chauhan D, Teoh G et al. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 2000;6:1180-1189.
84. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115.
85. Minn AJ, Rudin CM, Boise LH et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-1910.
86. Grad JM, Bahlis NJ, Reis I et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813.
87. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6[suppl 2]:22-28.
88. Brunet C, Luyckx M, Cazin M. Pharmacokinetics of arsenic trioxide in the mouse [in French]. Toxicol Eur Res 1982;4:175-179.
89. Hall LL, George SE, Kohan MJ et al. In vitro methylation of inorganic arsenic in mouse intestinal cecum. Toxicol Appl Pharmacol 1997;147:101-109.
90. Styblo M, Thomas DJ. Binding of arsenicals to proteins in an in vitro methylation system. Toxicol Appl Pharmacol 1997;147:1-8.
91. Beliles RP. Arsenic (As). In: Clayton GD, Clayton FE, eds. Patty's Industrial Hygiene and Toxicology, 4th ed. New York: John Wiley & Sons, 1994:1913-1925.
92. Fielder RJ, Dale EA, Williams SD. Toxicity Review 16: Inorganic Arsenic Compounds. London: HMSO Publications Centre, 1986:1-95.